Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBITDA (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EBITDA for 16 consecutive years, with $28.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 116.21% year-over-year to $28.5 million, compared with a TTM value of $236.1 million through Dec 2025, up 136.66%, and an annual FY2025 reading of $31.8 million, up 105.29% over the prior year.
  • EBITDA was $28.5 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $17.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $368.1 million in Q1 2025 and bottomed at -$177.7 million in Q2 2025.
  • Average EBITDA over 5 years is -$52.5 million, with a median of -$67.8 million recorded in 2021.
  • The sharpest move saw EBITDA crashed 366.45% in 2024, then skyrocketed 390.23% in 2025.
  • Year by year, EBITDA stood at -$62.9 million in 2021, then soared by 33.35% to -$41.9 million in 2022, then tumbled by 218.15% to -$133.4 million in 2023, then tumbled by 31.8% to -$175.8 million in 2024, then skyrocketed by 116.21% to $28.5 million in 2025.
  • Business Quant data shows EBITDA for ARWR at $28.5 million in Q4 2025, $17.2 million in Q3 2025, and -$177.7 million in Q2 2025.